{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 34,
  "pageCount": 415,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a screenshot of a Soleno clinical trial flow diagram to highlight patient drop-off.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "process_diagram"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/34",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-34",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The 13-week Phase 3 with 127 ITT patients dwindled to 83 by the end of the 52-week open-label extension, to 77 in the 16-week withdrawal study, to 60 start forms – leading us to infer a >50% discontinuation rate.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acac-902d35e763a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "image",
      "text": "Soleno’s investor presentation – clinical trials overview",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c41e5626-0a6f-4b73-81ba-a6f4f609bee1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "discontinuation rate: >50%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acac-9696cd3d1a19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "The company indicated receipt of 646 forms between March 26 FDA approval and June 30th. Of these, ~60 appear to be patients converting from the withdrawal study per management comments, implying significant attrition of patients on drug from the trials.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cee697f5-8fa0-4799-9793-5540dde2052a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "The 13-week Phase 3 with 127 ITT patients dwindled to 83 by the end of the 52-week open-label extension, to 77 in the 16-week withdrawal study, to 60 start forms – leading us to infer a >50% discontinuation rate.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f79e8076-8a1e-4269-a627-c1ba0fa0cbe2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://investors.soleno.life/static-files/48405466-3bcb-41d8-ae9e-76f388652c12",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1464da8-18c3-4f6d-b427-056417d57249",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Soleno’s launch metrics are vague, disclosing only start forms rather than total patients on drug – but they already indicate VYKAT XR has a high discontinuation rate.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a58da768-62fb-45f5-9fc4-e216642d8653",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "3f8c8f59-40d8-42e5-b76f-9629f502b508",
      "evidence": "The slide explicitly attempts to expose a contradiction between company-reported metrics and clinical trial attrition data.",
      "confidence": 0.85
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}